Reviving the patient’s immune system to destroy cancer—forever.™
TrAMPoline Pharma is a cellular immunotherapy company that is developing personalized (autologous) therapies for solid tumor cancers. Our lead therapeutic candidate, MightyTIL™ is a gene engineered tumor infiltrating lymphocyte (TIL) targeting orphan cancer indications (sarcoma, head and neck cancer) and melanoma. MightyTIL has demonstrated significantly enhanced anti-tumor activity in multiple animal tumor models as compared with conventional unmodified TIL.
TrAMPoline was founded with a vision to develop the next generation of cellular immunotherapies to treat solid tumor cancers, that make up 90% of all cancers. The unmet needs in the treatment of solid tumors are significant. ~60% of cancer patients experience T cell immunotherapy failures (including checkpoint inhibitors, CAR T cells, TCR-engineered, TIL). There are no FDA approved cellular therapies for solid tumors.
MightyTIL™ leverages TrAMPoline’s patented coR8:Amp™ technology which has potent dual functions - enhanced binding of the T cell receptor (TCR) to the cancer cells and enhanced TCR signaling domains that considerably increases the level of T cell activation and killing of cancer cells. MightyTILs demonstrates numerous advantages including the following.
Expanding reactivity to multiple tumor antigens. This is a critical factor in successfully treating cancer and preventing recurrence, since solid tumors mutate at a high rate forming cancer-specific neo-antigens targeted by MightyTILs. This feature offers an advantage over CAR T cells which recognize a single antigen which is often lost during cancer evolution.
MightyTILs show higher functional activity (potency) and increased expression of proliferation/survival receptors as compared with unmodified TILs.
MightyTILs demonstrate increased persistence and reduced exhaustion compared to unmodified TILs, due to reduction in expression of key checkpoint receptors.
MightyTILs are highly sensitive to the growth factor IL-2. Our pre-clinical studies demonstrate that MightyTILs require less IL-2 to generate potent anti-tumor responses. This is an important point as IL-2 toxicity in patients limits TIL efficacy.
MightyTILs exhibit long-lived anti-tumor activity as demonstrated by their ability to respond months after initially transferring them to hosts.
THE TRAMPOLINE PHARMA TEAM
Get to Know Us
EDUARDO DAVILA, PH.D.
Co-founder and Chief Scientific Officer
Eduardo Davila is a professor in the Department of Medicine, Medical Oncology at the University of Colorado, where serves as Director of Cancer Immunotherapy. His research and translational efforts focus on developing novel T cell-based immunotherapies. His research team has dissected the role of the MyD88 protein in augmenting T cells’ effector functions and persistence. Dr. Davila is also the inventor of the two patents that formed the key I.P. of startup Living Pharmaceuticals, Inc., which was acquired by Miltenyi Biotec in 2017. Its anti-tag chimeric antigen receptor (AT-CAR) engineered T cell therapy is expected to advance to Phase 1 clinical trials in Q4 of 2021.
RICHARD C DUKE, PH.D.
Dr. Duke is a biotechnology executive, inventor, biomedical researcher and serial entrepreneur with more than 20 years of experience in building, financing and managing start-up biotechnology companies based on inventions made in Colorado’s non-profit research institutions.
Dr. Duke is a co-scientific founder and former chief executive officer of GlobeImmune (NASD: GBIM) and was involved in the formation and/or management of Newellink, ApopLogic Pharmaceuticals, Sierra Neuropharmaceuticals, MenoGeniX, PeptiVir and Aurora Oncology. These Colorado-based companies have raised more than $200 million in financing and have multiple products in phase I and II clinical trials. Dr. Duke has more than 30 years of experience in biomedical research and is a tenured faculty member in the Department of Medicine at the University of Colorado Denver. He has more than 70 research publications and his work on apoptosis was recognized as the cover article of “Scientific American”. He is a graduate of McGill University (B.Sc. and M.Sc.) and the University of Colorado (Ph.D.).
Senior Advisor and Corporate Secretary
Darryl serves as an advisor to, and senior executive of, life science concerns. He provides strategic guidance and operational expertise to biotech companies and their boards, leveraging over 30 years of global corporate experience across human, animal and plant applications. His prior experience includes serving as an Officer and Senior Vice President, Intellectual Property, at Intrexon corporation, as well as a Senior Patent Counsel at Wyeth and AlliedSignal.
GET IN TOUCH
12635 E Montview Blvd., Suite 125 | Aurora, CO 80045